J R Mascola

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes
    Nicole A Doria-Rose
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:3393-7. 2012
  2. ncbi Vaccines for the prevention of HIV-1 disease
    J R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Immunol 13:489-95. 2001
  3. ncbi The role of antibodies in HIV vaccines
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 28:413-44. 2010
  4. ncbi Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
  5. ncbi Defining the protective antibody response for HIV-1
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Mol Med 3:209-16. 2003
  6. ncbi Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Dr, Bethesda, MD 20892, USA
    J Virol 79:771-9. 2005
  7. ncbi Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, MSC3015, Bethesda, MD 20892, USA
    J Virol 79:10103-7. 2005
  8. ncbi Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
    John R Mascola
    Vaccine Research Center, NIAID NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Vaccine 20:1922-5. 2002
  9. ncbi Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells
    John R Mascola
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:4810-21. 2002
  10. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
    J Infect Dis 194:1638-49. 2006

Detail Information

Publications82

  1. ncbi HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes
    Nicole A Doria-Rose
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:3393-7. 2012
    ..Predicted neutralization coverage of a combination of two MAbs reached 97% on a 208-isolate panel...
  2. ncbi Vaccines for the prevention of HIV-1 disease
    J R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Immunol 13:489-95. 2001
    ....
  3. ncbi The role of antibodies in HIV vaccines
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 28:413-44. 2010
    ..Thus, current vaccine design efforts have focused on a more detailed understanding of these broadly neutralizing antibodies and their epitopes to inform the design of improved vaccines...
  4. ncbi Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  5. ncbi Defining the protective antibody response for HIV-1
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Mol Med 3:209-16. 2003
    ..Based on these data, a major goal of HIV-1 vaccine strategies is the induction of neutralizing antibodies against circulating primary HIV-1 strains...
  6. ncbi Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Dr, Bethesda, MD 20892, USA
    J Virol 79:771-9. 2005
    ....
  7. ncbi Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
    John R Mascola
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, MSC3015, Bethesda, MD 20892, USA
    J Virol 79:10103-7. 2005
  8. ncbi Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
    John R Mascola
    Vaccine Research Center, NIAID NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Vaccine 20:1922-5. 2002
    ....
  9. ncbi Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells
    John R Mascola
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:4810-21. 2002
    ..The precision and reproducibility of this assay will facilitate the measurement of HIV-1 neutralization, particularly incrementally improved neutralizing antibody responses generated by new candidate vaccines...
  10. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA
    J Infect Dis 194:1638-49. 2006
    ..This multiclade rAd5 HIV-1 vaccine is now being evaluated in combination with a multiclade HIV-1 DNA plasmid vaccine...
  11. ncbi Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys
    Norman L Letvin
    Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 78:7490-7. 2004
    ....
  12. ncbi Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...
  13. ncbi Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007
    ..Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation...
  14. ncbi Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  15. ncbi Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model
    Srinivas S Rao
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:367-73. 2006
    ....
  16. ncbi Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys
    Norman L Letvin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1530-3. 2006
    ..These immune correlates of vaccine efficacy should guide the evaluation of AIDS vaccines in humans...
  17. ncbi Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
    Bimal K Chakrabarti
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    Vaccine 23:3434-45. 2005
    ..These studies suggest that combinations of Env immunogens, despite the limited reactivity of the V3 from each component, can be used to expand the breadth of the neutralizing antibody response...
  18. ncbi Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope
    Lan Wu
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Bldg. 40, MSC-3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA
    Vaccine 24:4995-5002. 2006
    ....
  19. ncbi Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens
    Mei Yun Zhang
    CCRNP, CCR, NCI Frederick, NIH, Bldg 469, Rm 131, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    J Virol 82:6869-79. 2008
    ..Its novel conserved conformational epitope on gp41 could be helpful in the design of vaccine immunogens and as a target for therapeutics...
  20. ncbi Neutralizing antibody quantification by flow cytometry
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Methods Cell Biol 75:709-16. 2004
  21. ncbi HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensi
    Mark K Louder
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Virology 339:226-38. 2005
    ..Replication competent HIV-1 and isogenic envelope pseudoviruses have similar neutralization characteristics, but passage into PBMC is associated with decreased sensitivity to neutralization...
  22. ncbi Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs
    Yuuei Shu
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Vaccine 25:1398-408. 2007
    ....
  23. ncbi A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
    ..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study...
  24. ncbi Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    Tongqing Zhou
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Science 329:811-7. 2010
    ..Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies...
  25. ncbi Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
    ..Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine...
  26. ncbi Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1
    Anita Changela
    Vaccine Research Center, NIAID NIH, 40 Convent Drive, Building 40, Room 4508, Bethesda, MD 20892 3027, USA
    J Virol 85:2524-35. 2011
    ....
  27. ncbi Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells
    Karin Lore
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 201:2023-33. 2005
    ..This suggests that the induction of antigen-specific T cell responses by DCs, a process crucial to immune defense, can lead to preferential HIV-1 infection and the deletion of responding CD4(+) T cells...
  28. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
    ..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens...
  29. ncbi Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
    Y Li
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Rm 4512, Bethesda, MD 20892, USA
    J Virol 80:1414-26. 2006
    ..Further mapping analysis of more conserved regions of gp120/gp41 may be required to determine the neutralizing specificity elicited by the trimeric immunogens...
  30. ncbi Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Instiutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10724-37. 2004
    ..Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed...
  31. ncbi A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
    Julie E Martin
    Vaccine Research Center, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Infect Dis 196:1732-40. 2007
    ..West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study...
  32. ncbi Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain
    Lan Wu
    Vaccine Research Center, NIAID, National Institutes of Health, Bldg 40, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    J Virol 83:5077-86. 2009
    ..Structurally designed membrane-anchored ODs represent candidate immunogens to elicit or to allow the detection of broadly neutralizing antibodies to the conserved site of CD4 binding on HIV-1 gp120...
  33. ncbi Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    Nicole A Doria-Rose
    LIR, NIAID, National Institutes of Health, Bldg 10, Rm 7N246, 10 Center Dr, Bethesda, MD 20892, USA
    J Virol 83:188-99. 2009
    ..These data describe the breadth and titer of serum NAb and the frequency and phenotype of HIV-specific B cells in a cohort of patients with broad cross-neutralizing antibody responses that are potential goals for vaccines for HIV...
  34. ncbi Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  35. ncbi Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2
    Jae Ouk Kim
    Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Bldg 40, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 81:1444-50. 2007
    ..Virions resistant to damage by antibody and complement were sensitive to lysis by sPLA2-X, suggesting a novel mechanism of antiviral surveillance independent of the acquired immune system...
  36. ncbi Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    Lei Chen
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 326:1123-7. 2009
    ..This incompatibility, the consequence of slight differences in CD4BS recognition, renders HIV-1 resistant to all but the most accurately targeted antibodies...
  37. ncbi Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region
    Gilad Ofek
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:2955-62. 2010
    ..Together, the results provide a more complete understanding of the 2F5 mechanism of HIV-1 neutralization and indicate ways to enhance the potency of MPER-directed antibodies...
  38. ncbi Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3027, USA
    J Virol 84:8098-110. 2010
    ..The structural and functional details of extraordinary CDR H3 and extensive affinity maturation provide insights into the neutralization mechanism of and the elicitation pathway for broadly neutralizing antibodies like PG9 and PG16...
  39. ncbi Immunologic and virologic events in early HIV infection predict subsequent rate of progression
    Anuradha Ganesan
    National Naval Medical Center, Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, Maryland 20892, USA
    J Infect Dis 201:272-84. 2010
    ..Because central memory T (T(CM)) cells play a critical role in the pathogenesis of simian immunodeficiency virus disease, we hypothesized that quantifying these cells in early HIV infection could provide prognostic information...
  40. ncbi B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4
    Mattias N E Forsell
    Vaccine Research Center, NIH, Bethesda, MD, USA
    PLoS Pathog 4:e1000171. 2008
    ....
  41. ncbi Broad HIV-1 neutralization mediated by CD4-binding site antibodies
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 13:1032-4. 2007
    ..Novel antibodies to the CD4-binding site are elicited in some HIV-1-infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens...
  42. ncbi Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses
    Xueling Wu
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    Virology 380:285-95. 2008
    ..These findings confirm that V3 antibodies recognize most primary viral strains, but that the epitope often has limited accessibility in the context of native envelope spike...
  43. ncbi Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope
    Zhi-Yong Yang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3005, USA
    J Virol 78:4029-36. 2004
    ..These findings suggest that highly conserved subregions within V3 may be relevant targets for eliciting neutralizing antibody responses, affecting HIV tropism, and increasing the immunogenicity of AIDS vaccines...
  44. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
    ..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses...
  45. ncbi Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity
    Barna Dey
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 81:5579-93. 2007
    ..Together, the results suggest that conformational stabilization may improve the ability of gp120 to elicit neutralizing antibodies...
  46. ncbi Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site
    Barna Dey
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA
    PLoS Pathog 5:e1000445. 2009
    ..These results demonstrate that structure-based approaches can be exploited to stabilize a conformational site in a large functional protein to enhance immunogenic responses specific for that region...
  47. ncbi Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment
    Xueling Wu
    Vaccine Research Center, NIAID, NIH, 40 Convent Dr, Bethesda, MD 20892, USA
    J Virol 83:10892-907. 2009
    ....
  48. ncbi Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1
    Peter D Kwong
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Cell Host Microbe 6:292-4. 2009
    ....
  49. ncbi Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
    Nicole A Doria-Rose
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:1631-6. 2010
    ..Clustering analysis of sera by a novel method identified a statistically robust subgrouping of sera that demonstrated broad and potent neutralization activity...
  50. ncbi The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes
    Lakshmanan Ganesh
    Vaccine Research Center, NIAID, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 426:853-7. 2003
    ..Through its effects on the proteasome, Murr1 acts as a genetic restriction factor that inhibits HIV-1 replication in lymphocytes, which could contribute to the regulation of asymptomatic HIV infection and the progression of AIDS...
  51. ncbi Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
    ..It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike...
  52. ncbi Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies
    Xueling Wu
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    J Virol 85:4578-85. 2011
    ..Quaternary structure-specific antibodies appear to target antigenic variants of the same epitope, with neutralization breadth determined by the prevalence of recognized variants among circulating isolates...
  53. ncbi The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 78:2394-404. 2004
    ....
  54. ncbi Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination
    Jamal Baig
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 76:11484-90. 2002
    ..These studies therefore suggest that systemic delivery of potent HIV immunogens may suffice to elicit substantial mucosal CTL responses...
  55. ncbi Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus
    Mattias N E Forsell
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    J Virol 79:10902-14. 2005
    ..This suggests that rSFV may be a useful component of a viral vector prime-protein boost regimen aimed at stimulating both cell-mediated immune responses and neutralizing antibodies against HIV-1...
  56. ncbi Immunoprophylaxis to prevent mother-to-child transmission of HIV-1
    Jeffrey T Safrit
    Elizabeth Glaser Pediatric AIDS Foundation, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Acquir Immune Defic Syndr 35:169-77. 2004
    ..Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years...
  57. ncbi HIV-1: nature's master of disguise
    John R Mascola
    Nat Med 9:393-4. 2003
  58. ncbi Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells
    Mary A Marovich
    Division of Retrovirology, US Military HIV Research Program, Rockville, Maryland 20850, USA
    J Infect Dis 186:1242-52. 2002
    ..These data support an ongoing HIV vaccine trial comparing conventional vaccine delivery routes with ex vivo vaccine-loaded autologous DCs for immunogenicity in HIV-1-uninfected volunteers...
  59. ncbi Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection
    Melody G Duvall
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom
    J Virol 81:13486-98. 2007
    ....
  60. ncbi Vaccines: engineering immune evasion
    John R Mascola
    Nature 441:161. 2006
  61. ncbi Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys
    Paula M Acierno
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA
    J Immunol 176:5338-45. 2006
    ....
  62. ncbi Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Virology 350:34-47. 2006
    ....
  63. ncbi Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:4753-60. 2005
    ..Persisting clinical protection in vaccinated and challenged monkeys is thus correlated with a preserved capacity of the peripheral blood central memory CD4+ T cells to express this important immunomodulatory cytokine...
  64. ncbi Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  65. ncbi Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
    ..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
  66. ncbi Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses
    Keith A Reimann
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 79:8878-85. 2005
    ....
  67. ncbi Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells
    Anna Smed-Sorensen
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, F59 Huddinge University Hospital, S 141 86 Stockholm, Sweden
    J Virol 79:8861-9. 2005
    ..The difference in susceptibility of PDCs and MDCs to HIV-1 may have implications for HIV-1 transmission and DC-mediated transfer of HIV-1 to T cells...
  68. ncbi Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave. RE-113, Boston, MA 02215, USA
    J Virol 79:4580-8. 2005
    ..These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination...
  69. ncbi Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave./RE-113, Boston, MA 02215, USA
    J Virol 79:2956-63. 2005
    ..This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1...
  70. ncbi Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, Boston, MA 02215, USA
    J Virol 80:10950-6. 2006
    ..These findings underscore the contribution of virus-specific central memory T lymphocytes to controlling clinical progression in vaccinated individuals following a primate immunodeficiency virus infection...
  71. ncbi HIV/AIDS: allied responses
    John R Mascola
    Nature 449:29-30. 2007
  72. ncbi No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys
    Norman L Letvin
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 81:12368-74. 2007
    ..Rather, innate immune mechanisms or an intact epithelial barrier may be responsible for protection against mucosal infection in this population of monkeys...
  73. ncbi Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Ave RE 204, Boston, MA 02215, USA
    Virology 367:175-86. 2007
    ....
  74. ncbi A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 79:8828-34. 2005
    ..This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans...
  75. ncbi Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote
    Paul R Gorry
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Virology 362:163-78. 2007
    ....
  76. ncbi Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination
    Lei Zhang
    Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, New South Wales 2052, Australia
    J Virol 78:5520-2. 2004
    ..By contrast, reduction in peak viral load later in infection prevents CD4 depletion and contributes to long-term viral control...
  77. ncbi Lessons from failure--preparing for future HIV-1 vaccine efficacy trials
    Barney S Graham
    J Infect Dis 191:647-9. 2005
  78. ncbi Gene transfer in humans using a conditionally replicating lentiviral vector
    Bruce L Levine
    Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 103:17372-7. 2006
    ..There is no evidence for insertional mutagenesis after 21-36 months of observation. Immune function improved in four subjects. Lentiviral vectors appear promising for gene transfer to humans...
  79. ncbi Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort
    Stephanie K Brodine
    Graduate School of Public Health, San Diego State University, San Diego, California 92182, USA
    AIDS 17:2521-7. 2003
    ..Efficient diagnosis of acute primary HIV-1 infection was identified as a goal for prevention programs. Modifiable risk behaviors and target populations for intervention were identified...
  80. ncbi Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel
    Sodsai Tovanabutra
    US Military HIV Research Program, Henry M. Jackson Foundation, Rockville, Maryland 20850, USA
    AIDS Res Hum Retroviruses 21:424-9. 2005
    ..S. military exposure while deployed and sets the bar higher for breadth of cross-subtype protection to be afforded by an HIV-1 vaccine...
  81. ncbi Demonstration of de novo HIV type 1 production by detection of multiply spliced and unspliced HIV type 1 RNA in paraffin-embedded tonsils
    Elena F Brachtel
    Department of Infectious and Parasitic Disease Pathology, Armed Forces Institute of Pathology (AFIP, Washington, DC 20306, USA
    AIDS Res Hum Retroviruses 18:785-90. 2002
    ..They also show the feasibility of performing molecular epidemiologic studies on HIV-1 cDNA sequences from archived pathologic specimens...
  82. ncbi Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins
    Hua Xin Liao
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Virol 78:5270-8. 2004
    ....